Literature DB >> 16721109

Prenatal therapy for fetal growth restriction.

Reinaldo Figueroa1, Dev Maulik.   

Abstract

The choice of therapy for fetal growth restriction (FGR) depends on the nature of the insult that led to the development of FGR. Many etiologic factors are either not amenable to therapy or fetal growth has not been improved by treatments that benefit the mother. Many therapeutic approaches have been used to improve fetal condition. None of the approaches have been of value in a consistent manner. We present the numerous approaches, and their rationale for their use, that have been tried to treat the growth impaired fetus. The evidence from the randomized clinical trials is summarized and their conclusions given.

Mesh:

Substances:

Year:  2006        PMID: 16721109     DOI: 10.1097/00003081-200606000-00012

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  4 in total

1.  Sildenafil increases uterine blood flow in nonpregnant nulliparous women.

Authors:  Sarah A Hale; Cresta W Jones; George Osol; Adrienne Schonberg; Gary J Badger; Ira M Bernstein
Journal:  Reprod Sci       Date:  2010-04       Impact factor: 3.060

Review 2.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

3.  In vivo MRI assessment of placental and foetal oxygenation changes in a rat model of growth restriction using blood oxygen level-dependent (BOLD) magnetic resonance imaging.

Authors:  S Aimot-Macron; L J Salomon; B Deloison; R Thiam; C A Cuenod; O Clement; N Siauve
Journal:  Eur Radiol       Date:  2013-02-26       Impact factor: 5.315

4.  Uteroplacental adenovirus vascular endothelial growth factor gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies.

Authors:  David J Carr; Jacqueline M Wallace; Raymond P Aitken; John S Milne; Vedanta Mehta; John F Martin; Ian C Zachary; Donald M Peebles; Anna L David
Journal:  Hum Gene Ther       Date:  2014-04-07       Impact factor: 5.695

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.